Perceptive Advisors LLC Increases Stock Holdings in Veru Inc. (NASDAQ:VERU)

Perceptive Advisors LLC lifted its stake in shares of Veru Inc. (NASDAQ:VERU) by 26.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 7,063,277 shares of the company’s stock after buying an additional 1,478,578 shares during the quarter. Perceptive Advisors LLC’s holdings in Veru were worth $5,942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Cetera Advisors LLC purchased a new position in Veru during the 1st quarter worth $33,000. Choreo LLC acquired a new position in shares of Veru during the first quarter worth about $64,000. Rhumbline Advisers increased its stake in shares of Veru by 3,994.8% during the second quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock worth $96,000 after acquiring an additional 110,857 shares during the period. SeaCrest Wealth Management LLC raised its holdings in Veru by 313.8% during the second quarter. SeaCrest Wealth Management LLC now owns 120,000 shares of the company’s stock worth $101,000 after purchasing an additional 91,000 shares in the last quarter. Finally, 180 Wealth Advisors LLC acquired a new stake in Veru in the first quarter valued at about $120,000. 47.16% of the stock is owned by institutional investors and hedge funds.

Veru Price Performance

Shares of VERU stock opened at $0.77 on Monday. The stock has a 50 day simple moving average of $0.85 and a 200-day simple moving average of $0.97. Veru Inc. has a 12-month low of $0.36 and a 12-month high of $1.92.

Veru (NASDAQ:VERU) last issued its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.01). The company had revenue of $3.95 million for the quarter, compared to analysts’ expectations of $3.50 million. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. Sell-side analysts expect that Veru Inc. will post -0.3 earnings per share for the current year.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.